Invivyd’s Strategic Advancements and Strong Financial Position Justify Buy Rating
I'm PortAI, I can summarize articles.
Analyst Patrick Trucchio of H.C. Wainwright has reiterated a Buy rating on Invivyd, maintaining a price target of $10.00. This rating is supported by Invivyd's strategic advancements, including a 41% year-over-year increase in PEMGARDA revenues and FDA clearance for VYD2311. The company's strong cash position, enhanced by recent fundraising, positions it well for future growth in COVID-19 prevention. Cantor Fitzgerald also supports this outlook with a Buy rating and a $10.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments